Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 46 to 60 of 61 results for endocrine cancers

  1. Age 'should not be barrier to treatment'

    Decisions around whether to offer a person surgical treatment should not be based on age and fitness, according to a new report.

    News
    Published
    17 October 2012

  2. Endoscopic mastectomy and endoscopic wide local excision for breast cancer (IPG296)

    Evidence-based recommendations on endoscopic mastectomy and endoscopic wide local excision for breast cancer. This involves removing part or all of the breast using special instruments inserted through small cuts in the skin (keyhole surgery).

    Interventional procedures guidance
    Published
    22 April 2009
    View recommendations

    Sections for IPG296

  3. Breast cancer guidelines

    This webpage covers NICE guidelines on breast cancer. The table below presents the guidelines alphabetically with links to the...

    NICE guideline
    In development

  4. Pembrolizumab with neoadjuvant chemotherapy and adjuvant endocrine therapy for treating ER-positive, HER2-negative early breast cancer [ID3993]

    Awaiting development [GID-TA10896] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Abemaciclib monotherapy for treating advanced hormone-receptor positive, HER2-negative breast cancer after endocrine therapy and chemotherapy [ID1347]

    Discontinued [GID-TA10264]

    Technology appraisal guidance
    Discontinued

  6. Everolimus with exemestane for treating HER2-negative hormone-receptor-positive breast cancer after endocrine therapy [ID965]

    Discontinued [GID-TA10028]

    Technology appraisal guidance
    Discontinued

  7. Ribociclib in combination with endocrine therapy and goserelin for previously untreated hormone receptor-positive, HER2-negative advanced breast cancer in premenopausal women (ID1307)

    In development [GID-TA10261] Expected publication date: TBC

    Technology appraisal guidance
    In development

  8. Selpercatinib for treating advanced thyroid cancer with RET alterations (MA review of TA742) [ID6288]

    Awaiting development [GID-TA11398] Expected publication date: 13 November 2024

    Technology appraisal guidance
    Awaiting development

  9. Palbociclib with trastuzumab and endocrine therapy for maintenance treatment of hormone-receptor positive, HER2-positive metastatic breast cancer [ID6251]

    Awaiting development [GID-TA11273] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Trastuzumab deruxtecan for treating hormone receptor-positive HER2-low metastatic breast cancer after 2 or more endocrine treatments [ID6226]

    Awaiting development [GID-TA11231] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Vepdegestrant for treating hormone receptor-positive HER2-negative metastatic breast cancer after endocrine treatment [ID6360]

    In development [GID-TA11400] Expected publication date: TBC

    Technology appraisal guidance
    In development

  12. Capivasertib with fulvestrant for treating hormone receptor-positive HER2-negative advanced breast cancer after endocrine treatment ID6370

    In development [GID-TA11513] Expected publication date: TBC

    Technology appraisal guidance
    In development

  13. Elacestrant for treating oestrogen receptor-positive, HER2-negative advanced breast cancer with an ESR1 mutation after at least 1 endocrine treatment [ID6225]

    In development [GID-TA11263] Expected publication date: TBC

    Technology appraisal guidance
    In development

  14. Imlunestrant for treating oestrogen receptor-positive HER2-negative advanced breast cancer after endocrine therapy ID6373

    In development [GID-TA11439] Expected publication date: TBC

    Technology appraisal guidance
    In development

  15. Ribociclib with an aromatase inhibitor for adjuvant treatment of hormone receptor-positive, HER2-negative early breast cancer [ID6153]

    In development [GID-TA11090] Expected publication date: TBC

    Technology appraisal guidance
    In development